生物製藥冷凍乾燥服務市場:按生物製藥類型(抗體、細胞/基因治療、疫苗、其他生物製藥)到冷凍乾燥,按初級包裝系統類型
市場調查報告書
商品編碼
1071811

生物製藥冷凍乾燥服務市場:按生物製藥類型(抗體、細胞/基因治療、疫苗、其他生物製藥)到冷凍乾燥,按初級包裝系統類型

Lyophilization Services Market for Biopharmaceuticals by Type of Biologic Lyophilized (Antibodies, Cell and Gene Therapies, Vaccines and Other Biologics), Type of Primary Packaging System

出版日期: | 出版商: Roots Analysis | 英文 225 Pages | 商品交期: 最快1-2個工作天內

價格

洞察例子

本報告調查了全球生物製藥冷凍乾燥服務市場,提供了市場概況、生物製藥冷凍乾燥類型的趨勢、初級包裝系統類型的趨勢以及進入市場的公司概況。

目錄

第一章前言

第2章執行摘要

第三章介紹

  • 章節概述
  • 冷凍乾燥概述
  • 凍乾生物製藥
  • 冷凍乾燥機及其主要成分
  • 用於冷凍乾燥生物製藥的初級包裝系統
  • 凍乾循環的開發與優化
  • 結束語

第四章市場情況

  • 章節概述
  • 生物製藥凍乾服務商:整體市場情況

第5章基準分析

  • 章節概述
  • 調查方法
  • 基準分析:同行組

第6章企業簡介:北美生物製藥凍乾服務商

  • 章節概述
  • 百特生物製藥解決方案
  • 庫裡亞
  • 新興生物解決方案
  • LSNE 合同製造
  • 凍乾技術

第7章企業簡介:歐洲生物製藥凍乾服務商

  • 章節概述
  • 科登製藥
  • 科裡奧利製藥
  • 北威生物
  • 項目製藥
  • 維特製藥

第8章企業簡介:亞太生物製藥凍乾服務商

  • 章節概述
  • BioZed 工程
  • MabPlex
  • 三星生物
  • 藥明生物

第 9 章夥伴關係和合作

第 10 章最近的擴展

第11章調查分析

  • 章節概述
  • 生物製藥凍乾服務市場:參與公司名單

第12章案例研究一:凍乾循環的開發與優化

第13章案例研究二:冷凍乾燥的替代方法

第 14 章市場預測和機會分析

  • 章節概述
  • 預測性調查方法和關鍵假設
  • 2022-2035 年全球生物製藥冷凍乾燥服務市場
  • 生物製藥凍乾服務市場:按凍乾生物製藥類型,2022 年和 2035 年
    • 抗體
    • 細胞/基因治療
    • 疫苗
    • 其他生物製品
  • 生物製藥凍乾服務市場:按初級包裝系統類型,2022 年和 2035 年
    • 小瓶
    • 注射器
    • 墨盒
    • 安瓿
    • 其他
  • 生物製藥凍乾服務市場:按地區分,2022 年和 2035 年
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和北非
    • 拉丁美洲
    • 其他領域

第15章結論

第 16 章執行洞察力

第十七章附錄一:聚合數據

第18章附錄2:公司和組織名單

Title:
Lyophilization Services
Market for Biopharmaceuticals by Type of Biologic Lyophilized (Antibodies, Cell and Gene Therapies, Vaccines and Other Biologics), Type of Primary Packaging System (Vials, Syringes, Cartridges, Ampoules and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Over the last decade, a steady rise has been observed in the annual number of approvals for various types of biologics (including monoclonal antibodies, cell therapies, recombinant proteins, vaccines and gene therapies). In addition, more than 8,000 biological therapeutics are currently being evaluated in clinical trials, being conducted across the globe. Evidently, biologics have emerged as one of the fastest growing segments in the pharmaceutical industry. Driven by several advantages offered by biologics over small molecules (including high efficacy, target specificity and favorable safety profiles) , the biopharmaceutical market is anticipated to witness continued and consistent growth over the next several years. However, there are a variety of challenges associated with such therapies. For instance, biological drugs are inherently less stable as compared to small molecules and, therefore, more prone to physical and chemical degradation. In order to achieve longer and commercially viable shelf lives, players are actively adopting the lyophilization (also known as freeze-drying) technique; it enables the production of stable dry biopharmaceutical formulations. In this context, it is worth highlighting that around 50% of the currently approved biopharmaceuticals are injectables. Of these, about one third of the drug candidates are being lyophilized.

Setting up in-house lyophilization capabilities and operations is an expensive and time-consuming process, which requires specialized lyophilization equipment and expertise. Considering the high capital investment and technical / routine operations-related challenges associated with lyophilization of biopharmaceuticals, a growing number of biologic developers are outsourcing their lyophilization operations to qualified contract manufacturing organizations (CMOs) in order to leverage their capabilities and yield cost savings opportunities. Presently, more than 105 contract manufacturers claim to have the required capabilities to offer lyophilization services for biotherapeutics. In addition, lyophilization service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance existing capabilities to meet the growing demand for biologics. Driven by the increasing preference for outsourcing, continuous growth of the biological therapeutics pipeline and a steady rise in drug approvals, the lyophilization services market for biopharmaceuticals is likely to witness steady growth in the foreseen future.

Scope of the Report

The "Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized (Antibodies, Cell and Gene Therapies, Vaccines and Other Biologics), Type of Primary Packaging System (Vials, Syringes, Cartridges, Ampoules and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of companies engaged in offering lyophilization services for biopharmaceuticals. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current landscape of companies offering lyophilization services for biopharmaceuticals, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, scale of operation (preclinical, clinical and commercial), regulatory certification / accreditation, type of biologic lyophilized (proteins, antibodies, vaccines, nucleic acids, cell / gene therapies, others and biologics (unspecified)) , process of lyophilization (bulk lyophilization and individual lyophilization) , type of primary packaging system (vials, pre-filled syringes, cartridges, ampoules and others) and additional services offered by the firms (lyophilization cycle development and lyophilization cycle optimization) .
  • An insightful benchmark analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia Pacific and RoW). The companies were further distributed across key geographies, based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees), highlighting the top players in this domain, based on their respective capabilities.
  • Elaborate profiles of prominent players offering lyophilization services for biopharmaceuticals, based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, covering acquisitions, asset acquisitions, product / technology development agreements, and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, most active players (in terms of number of partnerships) and regional distribution of the collaborations.
  • A detailed analysis of the recent expansions undertaken by various lyophilization service providers for biopharmaceuticals, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility addition), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.
  • A survey analysis presenting additional insights on lyophilization services offered for biopharmaceuticals, apart from those mentioned on the service provider's website. Inputs for this chapter were gathered across key parameters, including type of biologic lyophilized, type of primary packaging system, scale of operation, availability of lyophilization cycle development / optimization capabilities and location of dedicated manufacturing facility for lyophilization. Additionally, through the questionnaire we obtained some insights on the likely size of the current market for lyophilization services for biopharmaceuticals.
  • A case study on lyophilization cycle development and optimization services, highlighting the important parameters and techniques required for these processes. Further, the chapter presents the list of players that provide such services for biopharmaceuticals.
  • A case study on alternative approaches to the lyophilization process, such as spray drying, spray freeze drying, atmospheric spray freeze drying and vacuum foam drying.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for lyophilization services market for biopharmaceuticals over the coming decade. We have provided an informed estimate on the likely evolution of the market over the period 2022-2035. The report features a detailed forecast of the overall lyophilization services market for biopharmaceuticals, wherein both the current and upcoming opportunity is segmented across [A] type of biologic lyophilized (antibodies, cell and gene therapies, vaccines and other biologics) , [B] type of primary packaging system (vials, syringes, cartridges, ampoules and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world) . In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Brian Sasaki (Director of Business Development) and Thomas Ingallinera (Vice President of Technical Support), Pharmaceutical International
  • Doreen Coull (Regional Sales Director, Curia)
  • Patrick DePalma (Former Director of CMO Business Development, BioDefense Division, Emergent BioSolutions)
  • Rocio Gonzalez Rodriguez (Head of CDMO Project Management, Liof Pharma)
  • John Shaw (Former Head of Business Development and Marketing, Vibalogics)
  • Sophia Kim (Commercial DP (Depository Participant) Sales / Group Leader, Samsung Biologics)
  • Marianna Tcherpakov (Business Development Manager, Bioserv)
  • Adam Inche (Marketing Manager, Symbiosis Pharmaceutical Services)
  • Adam Viverette (Lyophilization Manager, Patheon)
  • Steven Nail (Principal Scientist, Baxter BioPharma Solutions)

Key Questions Answered:

  • Who are the key players engaged in offering lyophilization services for biopharmaceuticals?
  • What is the relative competitiveness of lyophilization service providers for biopharmaceuticals?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What are the different types of expansion initiatives being undertaken by lyophilization service providers for biopharmaceuticals?
  • What are the key market trends and driving factors that are likely to impact this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of lyophilization services market for biopharmaceuticals and its likely evolution in the short term, mid-term and long term.

Chapter 3 provides a general overview of the lyophilization process, its historical evolution, underlying principle, as well as associated advantages and disadvantages. The chapter also lays emphasis on lyophilization of biopharmaceuticals, along with various steps involved in the process. Furthermore, it features an elaborate discussion on the lyophilizer, its components and the primary packaging systems used for storage of the lyophilized formulations. It also presents information on lyophilization cycle development and optimization.

Chapter 4 features a detailed review of the current market landscape of around 105 companies offering lyophilization services for biopharmaceuticals. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also covers details about scale of operation (preclinical, clinical and commercial), regulatory certification / accreditation, type of biologic lyophilized (proteins, antibodies, vaccines, nucleic acids, cell / gene therapies, others and biologics (unspecified)), process of lyophilization (bulk lyophilization and individual lyophilization), type of primary packaging system (vials, pre-filled syringes, cartridges, ampoules and others) and additional services offered by the firms (lyophilization cycle development and lyophilization cycle optimization).

Chapter 5 presents an insightful benchmark analysis of the lyophilization service providers for biopharmaceuticals, located in North America, Europe, and Asia Pacific and RoW. The companies are further segmented based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees) across the key geographies. The analysis compares the service providers on the basis of various parameters, such as number of facilities, scale of operation, number of biologics lyophilized, process of lyophilization and number of primary packaging systems. In the chapter, the top stakeholders in each geography have been plotted on a spider web for their respective capabilities.

Chapter 6 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in North America. Each company profile features a brief overview of the company, details related to lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 7 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in Europe. Each company profile features a brief overview of the company, details related to its lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 8 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in Asia Pacific. Each company profile features a brief overview of the company, details related to its lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 9 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this domain, in the period 2018 - 2021. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (acquisitions, asset acquisitions, product / technology development agreements and others), most active player(s) (in terms of number of partnerships inked) and regional distribution of the collaborations.

Chapter 10 presents a detailed analysis of the recent expansions undertaken by various lyophilization service providers for biopharmaceuticals, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility additions), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.

Chapter 11 presents insights from the survey conducted for this study. We approached senior stakeholders from various companies involved in providing lyophilization services for biopharmaceuticals. The questionnaire primarily focused on type of biologic lyophilized, type of primary packaging system, scale of operation, availability of lyophilization cycle development / optimization capabilities and location of dedicated manufacturing facility for lyophilization. This helped us develop a deeper understanding on the nature of their services and the associated commercial potential. Additionally, we obtained some insights on the likely size of the current market of lyophilization services for biopharmaceuticals.

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on [A] type of biologic lyophilized (antibodies, cell and gene therapies, vaccines and other biologics), [B] type of primary packaging system (vials, syringes, cartridges, ampoules and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). It is worth mentioning that we adopted a top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research.

Chapter 13 presents elaborate details on lyophilization cycle development and optimization services, highlighting the important parameters and techniques required for these processes and the list of players offering such services for biopharmaceuticals.

Chapter 14 features a case study on alternative methods to the lyophilization process, such as spray drying, spray freeze drying, atmospheric spray freeze drying and vacuum foam drying. It specifically elaborates spray drying, covering information such as step-wise approach, applications of spray drying for biopharmaceuticals, key players providing such services and an informed comparison with lyophilization.

Chapter 15 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interview held with Brian Sasaki (Director of Business Development) and Thomas Ingallinera (Vice President of Technical Support), Pharmaceutical International, Doreen Coull (Regional Sales Director, Curia) , Patrick DePalma (Former Director of CMO Business Development, BioDefense Division, Emergent BioSolutions) , Rocio Gonzalez Rodriguez (Head of CDMO Project Management, Liof Pharma) , John Shaw (Former Head of Business Development and Marketing, Vibalogics) , Sophia Kim (Commercial DP (Depository Participant) Sales / Group Leader, Samsung Biologics) , Marianna Tcherpakov (Business Development Manager, Bioserv) , Adam Inche (Marketing Manager, Symbiosis Pharmaceutical Services) , Adam Viverette (Lyophilization Manager, Patheon) and Steven Nail (Principal Scientist, Baxter BioPharma Solutions) .

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Lyophilization
    • 3.2.1. Historical Evolution
    • 3.2.2. Underlying Principles
    • 3.2.3. Advantages and Disadvantages
  • 3.3. Lyophilization of Biopharmaceuticals
    • 3.3.1. Need for Lyophilization of Biopharmaceuticals
    • 3.3.2. Lyophilization Process
      • 3.3.2.1. Formulation and Filling
      • 3.3.2.2. Freezing
      • 3.3.2.3. Primary Drying
      • 3.3.2.4. Secondary Drying
  • 3.4. Lyophilizer and its Key Components
  • 3.5. Primary Packaging Systems Used for Lyophilization of Biopharmaceuticals
  • 3.6. Lyophilization Cycle Development and Optimization
  • 3.7. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Regulatory Certification / Accreditation
    • 4.2.6. Analysis by Type of Biologic Lyophilized
    • 4.2.7. Analysis by Process of Lyophilization
    • 4.2.8. Analysis by Type of Primary Packaging System
    • 4.2.9. Analysis by Additional Services Offered

5. BENCHMARK ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Benchmark Analysis: Peer Groups
    • 5.3.1. Benchmark Analysis: North America (Peer Group I)
    • 5.3.2. Benchmark Analysis: North America (Peer Group II)
    • 5.3.3. Benchmark Analysis: North America (Peer Group III)
    • 5.3.4. Benchmark Analysis: Europe (Peer Group IV)
    • 5.3.5. Benchmark Analysis: Europe (Peer Group V)
    • 5.3.6. Benchmark Analysis: Europe (Peer Group VI)
    • 5.3.7. Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VII)
    • 5.3.8. Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VIII)

6. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. Baxter BioPharma Solutions
    • 6.2.1. Company Overview
    • 6.2.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 6.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Curia
    • 6.3.1. Company Overview
    • 6.3.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 6.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. Emergent BioSolutions
    • 6.4.1. Company Overview
    • 6.4.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 6.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. LSNE Contract Manufacturing
    • 6.5.1. Company Overview
    • 6.5.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 6.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Lyophilization Technology
    • 6.6.1. Company Overview
    • 6.6.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 6.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN EUROPE

  • 7.1. Chapter Overview
  • 7.2. CordenPharma
    • 7.2.1. Company Overview
    • 7.2.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 7.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. Coriolis Pharma
    • 7.3.1. Company Overview
    • 7.3.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 7.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. Northway Biotech
    • 7.4.1. Company Overview
    • 7.4.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 7.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. ProJect Pharmaceutics
    • 7.5.1. Company Overview
    • 7.5.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 7.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Vetter Pharma
    • 7.6.1. Company Overview
    • 7.6.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 7.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN ASIA PACIFIC

  • 8.1. Chapter Overview
  • 8.2. BioZed Engineering
    • 8.2.1. Company Overview
    • 8.2.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 8.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. CinnaGen
    • 8.3.1. Company Overview
    • 8.3.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 8.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. MabPlex
    • 8.4.1. Company Overview
    • 8.4.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 8.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Samsung Biologics
    • 8.5.1. Company Overview
    • 8.5.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 8.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. WuXi Biologics
    • 8.6.1. Company Overview
    • 8.6.2. Lyophilization Service Offerings for Biopharmaceuticals
    • 8.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
    • 8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Most Active Players: Analysis by Number of Partnerships
    • 9.3.5. Analysis by Geography
      • 9.3.5.1. Intercontinental and Intracontinental Deals
      • 9.3.5.2. International and Local Deals

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
  • 10.2. Lyophilization Services Market for Biopharmaceuticals: List of Recent Expansions
    • 10.2.1. Analysis by Year of Expansion
    • 10.2.2. Analysis by Type of Expansion
    • 10.2.3. Analysis by Year and Type of Expansion
    • 10.2.4. Analysis by Company Size and Location of Headquarters
    • 10.2.5. Analysis by Location of Expanded Facility
    • 10.2.6. Active Players: Analysis by Number of Recent Expansions
    • 10.2.7. Analysis by Geography

11. SURVEY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Lyophilization Services Market for Biopharmaceuticals: List of Participating Companies
    • 11.2.1. Analysis by Seniority Level of Respondents
    • 11.2.2 Analysis by Type of Biologic Lyophilized
    • 11.2.3. Analysis by Type of Primary Packaging System
    • 11.2.4. Analysis by Scale of Operation
    • 11.2.5. Analysis by Additional Services Offered
    • 11.2.6. Analysis by Location of Lyophilization Facility
    • 11.2.7. Analysis by Share of Lyophilization Operations Outsourced
    • 11.2.8. Analysis by Likely Market Size
    • 11.2.9. Analysis of Likely Market Share by Type of Biologic Lyophilized
    • 11.2.10. Analysis of Likely Market Share by Geography

12. CASE STUDY I: LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION

  • 12.1. Chapter Overview
  • 12.2. Lyophilization Cycle Development
  • 12.3. Lyophilization Cycle Optimization
  • 12.4. Lyophilization Cycle Development and Optimization: List of Service Providers
    • 12.4.1. Analysis by Company Size
    • 12.4.2. Analysis by Location of Headquarters
    • 12.4.3. Analysis by Type of Service Offered
    • 12.4.4 Lyophilization Cycle Development and Optimization Service Providers: Company Snapshots

13. CASE STUDY II: ALTERNATIVE APPROACHES TO LYOPHILIZATION

  • 13.1. Chapter Overview
  • 13.2. Alternative Approaches to Lyophilization
    • 13.2.1. Spray Drying
      • 13.2.1.1. Spray Drying Process
      • 13.2.1.2. Applications of Spray Drying
      • 13.2.1.3. Spray Drying of Biopharmaceuticals
      • 13.2.1.4. Spray Drying Service Providers for Biopharmaceuticals
      • 13.2.1.5. Comparison of Lyophilization and Spray Drying
    • 13.2.2. Spray Freeze Drying
    • 13.2.3. Atmospheric Spray Freeze Drying
    • 13.2.4. Vacuum Foam Drying

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology and Key Assumptions
  • 14.3. Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035
  • 14.4. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035
    • 14.4.1. Lyophilization Services Market for Antibodies, 2022-2035
    • 14.4.2. Lyophilization Services Market for Cell and Gene Therapies, 2022-2035
    • 14.4.3. Lyophilization Services Market for Vaccines, 2022-2035
    • 14.4.4. Lyophilization Services Market for Other Biologics, 2022-2035
  • 14.5. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035
    • 14.5.1. Lyophilization Services Market for Biopharmaceuticals for Vials, 2022-2035
    • 14.5.2. Lyophilization Services Market for Biopharmaceuticals for Syringes, 2022-2035
    • 14.5.3. Lyophilization Services Market for Biopharmaceuticals for Cartridges, 2022-2035
    • 14.5.4. Lyophilization Services Market for Biopharmaceuticals for Ampoules, 2022-2035
    • 14.5.5. Lyophilization Services Market for Biopharmaceuticals for Other Primary Packaging Systems, 2022-2035
  • 14.6. Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035
    • 14.6.1. Lyophilization Services Market for Biopharmaceuticals in North America, 2022-2035
    • 14.6.2. Lyophilization Services Market for Biopharmaceuticals in Europe, 2022-2035
    • 14.6.3. Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022-2035
    • 14.6.4. Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022-2035
    • 14.6.5. Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022-2035
    • 14.6.6. Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022-2035

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

  • 16.1. Chapter Overview
  • 16.2. Pharmaceutical International
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Brian Sasaki, Director of Business Development and Thomas Ingallinera, Vice President of Technical Support
  • 16.3. Curia
    • 16.3.1. Company Snapshot
    • 16.3.2. Interview Transcript: Doreen Coull, Regional Sales Director
  • 16.4. Emergent BioSolutions
    • 16.4.1. Company Snapshot
    • 16.4.2. Interview Transcript: Patrick DePalma, Former Director, CMO Business Development, BioDefense Division
  • 16.5. Liof Pharma
    • 16.5.1. Company Snapshot
    • 16.5.2. Interview Transcript: Rocio Gonzalez Rodriguez, Head of CDMO Project Management
  • 16.6. Vibalogics
    • 16.6.1. Company Snapshot
    • 16.6.2. Interview Transcript: John Shaw, Former Head of Business Development and Marketing
  • 16.7. Samsung Biologics
    • 16.7.1. Company Snapshot
    • 16.7.2. Interview Transcript: Sophia Kim, Commercial DP (Depository Participant) Sales / Group Leader
  • 16.8. Bioserv
    • 16.8.1. Company Snapshot
    • 16.8.2. Interview Transcript: Marianna Tcherpakov, Business Development Manager
  • 16.9. Symbiosis Pharmaceutical Services
    • 16.9.1. Company Snapshot
    • 16.9.2. Interview Transcript: Adam Inche, Marketing Manager
  • 16.10. Patheon
    • 16.10.1. Company Snapshot
    • 16.10.2. Interview Transcript: Adam Viverette, Manager of Lyophilization Operations
  • 16.11. Baxter BioPharma Solutions
    • 16.11.1. Company Snapshot
    • 16.11.2. Interview Transcript: Steven Nail, Principal Scientist

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Partnerships and Collaborations
  • Figure 2.3 Executive Summary: Recent Expansions
  • Figure 2.4 Executive Summary: Survey Analysis
  • Figure 2.5 Executive Summary: Market Forecast
  • Figure 3.1 Historical Evolution of Lyophilization
  • Figure 3.2 Phase Diagram of Water
  • Figure 3.3 Sublimation of Ice Crystals
  • Figure 3.4 Key Steps Involved in Formulation and Filling of Biopharmaceuticals
  • Figure 3.5 Key Components of Lyophilizer
  • Figure 4.1 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Year of Establishment
  • Figure 4.2 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Company Size
  • Figure 4.3 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Location of Headquarters
  • Figure 4.4 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Scale of Operation
  • Figure 4.5 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Regulatory Certification / Accreditation
  • Figure 4.6 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized
  • Figure 4.7 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Process of Lyophilization
  • Figure 4.8 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Primary Packaging System
  • Figure 4.9 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Additional Services Offered
  • Figure 5.1 Benchmark Analysis: Distribution by Company Size
  • Figure 5.2 Benchmark Analysis: North America (Peer Group I)
  • Figure 5.3 Benchmark Analysis: North America (Peer Group II)
  • Figure 5.4 Benchmark Analysis: North America (Peer Group III)
  • Figure 5.5 Benchmark Analysis: Europe (Peer Group IV)
  • Figure 5.6 Benchmark Analysis: Europe (Peer Group V)
  • Figure 5.7 Benchmark Analysis: Europe (Peer Group VI)
  • Figure 5.8 Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VII)
  • Figure 5.9 Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VIII)
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 9.6 Partnerships and Collaborations: International and Local Deals
  • Figure 10.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2021
  • Figure 10.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 10.3 Recent Expansions: Distribution by Year and Type of Expansion
  • Figure 10.4 Recent Expansions: Distribution by Company Size and Location of Headquarters
  • Figure 10.5 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 10.6 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
  • Figure 10.7 Active Players: Distribution by Number of Recent Expansions
  • Figure 10.8 Recent Expansions: Distribution by Geography
  • Figure 11.1 Survey Analysis: Distribution by Geographical Location of Respondents
  • Figure 11.2 Survey Analysis: Distribution by Seniority Levels of Respondents
  • Figure 11.3 Survey Analysis: Distribution by Type of Biologic Lyophilized
  • Figure 11.4 Survey Analysis: Distribution by Type of Primary Packaging System
  • Figure 11.5 Survey Analysis: Distribution by Scale of Operation
  • Figure 11.6 Survey Analysis: Distribution by Additional Services Offered
  • Figure 11.7 Survey Analysis: Distribution by Location of Lyophilization Facility
  • Figure 11.8 Survey Analysis: Distribution by Share of Lyophilization Operations Outsourced
  • Figure 11.9 Survey Analysis: Distribution by Likely Current Market Size
  • Figure 11.10 Survey Analysis: Distribution of Likely Market Share by Type of Biologic Lyophilized
  • Figure 11.11 Survey Analysis: Distribution of Likely Market Share by Geography
  • Figure 12.1 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Company Size
  • Figure 12.2 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Location of Headquarters
  • Figure 12.3 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Type of Service Offered
  • Figure 13.1 Key Steps Involved in Spray Drying Process
  • Figure 14.1 Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035 (USD Billion)
  • Figure 14.2 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035 (USD Billion)
  • Figure 14.3 Lyophilization Services Market for Antibodies, 2022-2035 (USD Billion)
  • Figure 14.4 Lyophilization Services Market for Cell and Gene Therapies, 2022-2035 (USD Billion)
  • Figure 14.5 Lyophilization Services Market for Vaccines, 2022-2035 (USD Billion)
  • Figure 14.6 Lyophilization Services Market for Other Biologics, 2022-2035 (USD Billion)
  • Figure 14.7 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035 (USD Billion)
  • Figure 14.8 Lyophilization Services Market for Biopharmaceuticals Stored in Vials, 2022-2035 (USD Billion)
  • Figure 14.9 Lyophilization Services Market for Biopharmaceuticals Stored in Syringes, 2022- 2035 (USD Billion)
  • Figure 14.10 Lyophilization Services Market for Biopharmaceuticals Stored in Cartridges, 2022-2035 (USD Billion)
  • Figure 14.11 Lyophilization Services Market for Biopharmaceuticals Stored in Ampoules, 2022-2035 (USD Billion)
  • Figure 14.12 Lyophilization Services Market for Biopharmaceuticals Stored in Other Primary Packaging Systems, 2022-2035 (USD Billion)
  • Figure 14.13 Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Figure 14.14 Lyophilization Services Market for Biopharmaceuticals in North America, 2022- 2035 (USD Billion)
  • Figure 14.15 Lyophilization Services Market for Biopharmaceuticals in Europe, 2022- 2035 (USD Billion)
  • Figure 14.16 Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022- 2035 (USD Billion)
  • Figure 14.17 Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022- 2035 (USD Billion)
  • Figure 14.18 Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022- 2035 (USD Billion)
  • Figure 14.19 Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022- 2035 (USD Billion)
  • Figure 15.1 Concluding Remarks: Overall Market Landscape
  • Figure 15.2 Concluding Remarks: Benchmark Analysis
  • Figure 15.3 Concluding Remarks: Partnership and Collaborations
  • Figure 15.4 Concluding Remarks: Recent Expansions
  • Figure 15.5 Concluding Remarks: Market Forecast

List Of Tables

  • Table 4.1 List of Lyophilization Service Providers for Biopharmaceuticals
  • Table 5.1 Benchmark Analysis: Information on Peer Groups
  • Table 6.1 Leading Lyophilization Service Providers for Biopharmaceuticals in North America
  • Table 6.2 Baxter BioPharma Solutions: Company Snapshot
  • Table 6.3 Baxter BioPharma Solutions: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 6.4 Baxter BioPharma Solutions: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 6.5 Baxter BioPharma Solutions: Recent Developments and Future Outlook
  • Table 6.6 Curia: Company Snapshot
  • Table 6.7 Curia: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 6.8 Curia: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 6.9 Curia: Recent Developments and Future Outlook
  • Table 6.10 Emergent BioSolutions: Company Snapshot
  • Table 6.11 Emergent BioSolutions: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 6.12 Emergent BioSolutions: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 6.13 Emergent BioSolutions: Recent Developments and Future Outlook
  • Table 6.14 LSNE Contract Manufacturing: Company Snapshot
  • Table 6.15 LSNE Contract Manufacturing: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 6.16 LSNE Contract Manufacturing: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 6.17 LSNE Contract Manufacturing: Recent Developments and Future Outlook
  • Table 6.18 Lyophilization Technology: Company Snapshot
  • Table 6.19 Lyophilization Technology: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 6.20 Lyophilization Technology: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 6.21 Lyophilization Technology: Recent Developments and Future Outlook
  • Table 7.1 Leading Lyophilization Service Providers for Biopharmaceuticals in Europe
  • Table 7.2 CordenPharma: Company Snapshot
  • Table 7.3 CordenPharma: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 7.4 CordenPharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 7.5 CordenPharma: Recent Developments and Future Outlook
  • Table 7.6 Coriolis Pharma: Company Snapshot
  • Table 7.7 Coriolis Pharma: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 7.8 Coriolis Pharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 7.9 Coriolis Pharma: Recent Developments and Future Outlook
  • Table 7.10 Northway Biotech: Company Snapshot
  • Table 7.11 Northway Biotech: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 7.12 Northway Biotech: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 7.13 Northway Biotech: Recent Developments and Future Outlook
  • Table 7.14 ProJect Pharmaceutics: Company Snapshot
  • Table 7.15 ProJect Pharmaceutics: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 7.16 ProJect Pharmaceutics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 7.17 Vetter Pharma: Company Snapshot
  • Table 7.18 Vetter Pharma: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 7.19 Vetter Pharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 7.20 Vetter Pharma: Recent Developments and Future Outlook
  • Table 8.1 Leading Lyophilization Service Providers for Biopharmaceuticals in Asia Pacific
  • Table 8.2 BioZed Engineering: Company Snapshot
  • Table 8.3 BioZed Engineering: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 8.4 BioZed Engineering: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 8.5 BioZed Engineering: Recent Developments and Future Outlook
  • Table 8.6 CinnaGen: Company Snapshot
  • Table 8.7 CinnaGen: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 8.8 CinnaGen: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 8.9 CinnaGen: Recent Developments and Future Outlook
  • Table 8.9 MabPlex: Company Snapshot
  • Table 8.10 MabPlex: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 8.11 MabPlex: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 8.12 MabPlex: Recent Developments and Future Outlook
  • Table 8.13 Samsung Biologics: Company Snapshot
  • Table 8.14 Samsung Biologics: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 8.15 Samsung Biologics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 8.16 Samsung Biologics: Recent Developments and Future Outlook
  • Table 8.17 WuXi Biologics: Company Snapshot
  • Table 8.18 WuXi Biologics: Lyophilization Service Offerings for Biopharmaceuticals
  • Table 8.19 WuXi Biologics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
  • Table 8.20 WuXi Biologics: Recent Developments and Future Outlook
  • Table 9.1 Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations, 2018-2021
  • Table 10.1 Lyophilization Services for Biopharmaceuticals: List of Recent Expansions, 2018-2021
  • Table 11.1 Lyophilization Services Market for Biopharmaceuticals: List of Respondents
  • Table 12.1 Lyophilization Cycle Development and Optimization: List of Service Providers
  • Table 12.2 BSP Pharmaceuticals: Company Snapshot
  • Table 12.3 CuriRx: Company Snapshot
  • Table 12.4 GILYOS: Company Snapshot
  • Table 12.5 Pierre Fabre: Company Snapshot
  • Table 12.6 Singota Solutions: Company Snapshot
  • Table 13.1 Spray Drying for Biopharmaceuticals: List of Service Providers
  • Table 13.2 Comparison of Lyophilization and Spray Drying Process
  • Table 16.1 Pharmaceutical International: Company Snapshot
  • Table 16.2 Curia: Company Snapshot
  • Table 16.3 Emergent BioSolutions: Company Snapshot
  • Table 16.4 Liof Pharma: Company Snapshot
  • Table 16.5 Vibalogics: Company Snapshot
  • Table 16.6 Samsung Biologics: Company Snapshot
  • Table 16.7 Bioserv: Company Snapshot
  • Table 16.8 Symbiosis Pharmaceutical Services: Company Snapshot
  • Table 16.9 Patheon: Company Snapshot
  • Table 16.10 Baxter BioPharma Solutions: Company Snapshot
  • Table 17.1 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Year of Establishment
  • Table 17.2 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Company Size
  • Table 17.3 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Location of Headquarters
  • Table 17.4 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Scale of Operation
  • Table 17.5 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Regulatory Certification / Accreditation
  • Table 17.6 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized
  • Table 17.7 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Process of Lyophilization
  • Table 17.8 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Primary Packaging System
  • Table 17.9 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Additional Services Offered
  • Table 17.10 Benchmark Analysis: Asia Pacific and Rest of the World, Peer Group VII
  • Table 17.11 Benchmark Analysis: Asia Pacific and Rest of the World, Peer Group VIII
  • Table 17.12 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
  • Table 17.13 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.14 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 17.15 Most Active Players: Distribution by Number of Partnerships
  • Table 17.16 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 17.17 Partnerships and Collaborations: International and Local Deals
  • Table 17.18 Recent Expansions: Cumulative Year-wise Trend, 2018-2021
  • Table 17.19 Recent Expansions: Distribution by Type of Expansion
  • Table 17.20 Recent Expansions: Distribution by Year and Type of Expansion
  • Table 17.21 Recent Expansions: Distribution by Company Size and Location of Headquarters
  • Table 17.22 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 17.23 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
  • Table 17.24 Active Players: Distribution by Number of Recent Expansions
  • Table 17.25 Recent Expansions: Distribution by Geography
  • Table 17.26 Survey Analysis: Distribution by Geographical Location of Respondents
  • Table 17.27 Survey Analysis: Distribution by Seniority Levels of Respondents
  • Table 17.28 Survey Analysis: Distribution by Type of Biologic Lyophilized
  • Table 17.29 Survey Analysis: Distribution by Type of Primary Packaging System
  • Table 17.30 Survey Analysis: Distribution by Scale of Operation
  • Table 17.31 Survey Analysis: Distribution by Additional Services Offered
  • Table 17.32 Survey Analysis: Distribution by Location of Lyophilization Facility
  • Table 17.33 Survey Analysis: Distribution by Share of Lyophilization Operations Outsourced
  • Table 17.34 Survey Analysis: Distribution by Likely Current Market Size
  • Table 17.35 Survey Analysis: Distribution of Likely Market Share by Type of Biologic Lyophilized
  • Table 17.36 Survey Analysis: Distribution Likely Market Share by Geography
  • Table 17.37 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Company Size
  • Table 17.38 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Location of Headquarters
  • Table 17.39 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Type of Service Offered
  • Table 17.40 Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035 (USD Billion)
  • Table 17.41 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035 (USD Billion)
  • Table 17.42 Lyophilization Services Market for Antibodies, 2022-2035 (USD Billion)
  • Table 17.43 Lyophilization Services Market for Cell and Gene Therapies, 2022-2035 (USD Billion)
  • Table 17.44 Lyophilization Services Market for Vaccines, 2022-2035 (USD Billion)
  • Table 17.45 Lyophilization Services Market for Other Biologics, 2022-2035 (USD Billion)
  • Table 17.46 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035 (USD Billion)
  • Table 17.47 Lyophilization Services Market for Biopharmaceuticals Stored in Vials, 2022-2035 (USD Billion)
  • Table 17.48 Lyophilization Services Market for Biopharmaceuticals Stored in Syringes, 2022- 2035 (USD Billion)
  • Table 17.49 Lyophilization Services Market for Biopharmaceuticals Stored in Cartridges, 2022- 2035 (USD Billion)
  • Table 17.50 Lyophilization Services Market for Biopharmaceuticals Stored in Ampoules, 2022- 2035 (USD Billion)
  • Table 17.51 Lyophilization Services Market for Biopharmaceuticals Stored in Other Primary Packaging Systems, 2022- 2035 (USD Billion)
  • Table 17.52 Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Table 17.53 Lyophilization Services Market for Biopharmaceuticals in North America, 2022- 2035 (USD Billion)
  • Table 17.54 Lyophilization Services Market for Biopharmaceuticals in Europe, 2022- 2035 (USD Billion)
  • Table 17.55 Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022- 2035 (USD Billion)
  • Table 17.56 Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022- 2035 (USD Billion)
  • Table 17.57 Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022- 2035 (USD Billion)
  • Table 17.58 Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022- 2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  • 1. AbbVie
  • 2. Affinity Biologicals (Acquired by Precision BioLogic)
  • 3. Affinity Life Sciences
  • 4. Air Products
  • 5. Ajinomoto Bio-Pharma Services
  • 6. Alcami
  • 7. APTSol
  • 8. Arbor Investments
  • 9. Argonaut Manufacturing Services
  • 10. Attwill Medical Solutions
  • 11. Axcellerate Pharma (Acquired by Generic Specialties)
  • 12. Baccinex
  • 13. Basic Pharma
  • 14. Baxter BioPharma Solutions
  • 15. Berkshire Sterile Manufacturing
  • 16. BioConnection
  • 17. Biofortuna
  • 18. BIOLYPH
  • 19. Biopharma Group
  • 20. BioReliance
  • 21. Bioserv
  • 22. BioTechLogic
  • 23. BioTechnique
  • 24. BioZed Engineering
  • 25. Boehringer Ingelheim
  • 26. Bovogen Biologicals
  • 27. Bryllan
  • 28. BSP Pharmaceuticals
  • 29. Burrard Pharmaceuticals
  • 30. Canada Peptide
  • 31. CARBOGEN AMCIS (Acquired by Dishman Pharmaceuticals and Chemicals)
  • 32. Catalent
  • 33. Cenexi
  • 34. CinnaGen
  • 35. CoolVacuum (Acquired by Dara Pharma)
  • 36. CordenPharma
  • 37. Coriolis Pharma
  • 38. Curia
  • 39. CuriRx
  • 40. Dalton Pharma Services (Acquired by Seikagaku)
  • 41. Dara Pharmaceutical Equipment
  • 42. DavosPharma
  • 43. Emergent BioSolutions
  • 44. EnWave
  • 45. Eurofins
  • 46. Eurogentec
  • 47. Eurolyo (A Subsidiary of Groupe)
  • 48. European Medical Contract Manufacturing (EMCM)
  • 49. FAMAR
  • 50. Flow Sciences
  • 51. Fluorogenics (Acquired by New England Biolabs)
  • 52. Fresenius Kabi
  • 53. GEA
  • 54. GeneMe
  • 55. GILYOS
  • 56. Gipharma (Acquired by Advanced Accelerator Applications)
  • 57. GlaxoSmithKline (GSK)
  • 58. Goodwin Biotechnology
  • 59. GP Pharm
  • 60. Grand River Aseptic Manufacturing (GRAM)
  • 61. Groupe Berkem
  • 62. HALIX
  • 63. HTD Biosystems
  • 64. Hycult Biotech
  • 65. IBEX Pharmaceuticals
  • 66. IDT Biologika
  • 67. Integrated DNA Technologies (IDT)
  • 68. Integrity Bio (Acquired by Curia)
  • 69. IRISYS (Acquired by Societal CDMO)
  • 70. Jubilant HollisterStier
  • 71. KABS Pharmaceutical Services
  • 72. Kemp Proteins
  • 73. Kemwell Biopharma
  • 74. Lab-i-DOSiTECNO Pharma Technologies
  • 75. Labyrinth BioPharma (Formerly known as AB BioTechnologies)
  • 76. LakePharma (Acquired by Curia)
  • 77. Liof Pharma
  • 78. Lonza
  • 79. LSNE Contract Manufacturing (Acquired by PCI Pharma Services)
  • 80. Luina Bio
  • 81. LYOCONTRACT
  • 82. LyoGen (Acquired by Argonaut Manufacturing Services)
  • 83. LyoHUB
  • 84. Lyophilization Technology (LTI)
  • 85. MabPlex
  • 86. MBU-Technology
  • 87. Medicago
  • 88. Miltenyi Biotec
  • 89. Mycenax Biotech
  • 90. nanoTools Antibody Technology
  • 91. National Collection of Industrial, Food and Marine Bacteria (NCIMB)
  • 92. Nektar Therapeutics
  • 93. New England Biolabs (NEB)
  • 94. Nitto Avecia Pharma Services
  • 95. Northway Biotech
  • 96. Oncotec Pharma Produktion
  • 97. OPTIMA pharma
  • 98. Oregon Freeze Dry (Acquired by Arbor Investments)
  • 99. Parker Freeze Dry
  • 100. Patheon (Acquired by Thermo Fischer Scientific)
  • 101. PaxVax
  • 102. PCI Pharma Services
  • 103. Pfizer CentreOne
  • 104. Pharma Gen
  • 105. Pharmaceutics International
  • 106. Pierre Fabre
  • 107. Piramal Pharma Solutions
  • 108. Precision BioLogic
  • 109. Premas Biotech
  • 110. Profacgen
  • 111. ProForm Fabrication
  • 112. ProJect Pharmaceutics
  • 113. PSC Biotech
  • 114. PYRAMID Laboratories
  • 115. Quality BioResources
  • 116. Recipharm
  • 117. Rentschler Fill Solutions
  • 118. Resilience
  • 119. SafeBridge Consultants
  • 120. Samsung Biologics
  • 121. Seikagaku
  • 122. Sentinel Diagnostics
  • 123. Singota Solutions
  • 124. SP Scientific
  • 125. Sublime Stericeuticals
  • 126. Symbiosis Pharmaceutical Services
  • 127. SynCo Bio Partners
  • 128. SYNERLAB Group
  • 129. Therapure Biopharma (Acquired by Resilience)
  • 130. TriPharm Services (Acquired by Alcami)
  • 131. Vetter Pharma
  • 132. Vibalogics
  • 133. VxP Pharma
  • 134. Wacker Biotech
  • 135. WuXi Biologics